
ImmunoGen is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 277 staff and has a trailing 12-month revenue of around $108.8 million.
How to buy ImmunoGen stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IMGN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
ImmunoGen stock price (NASDAQ: IMGN)
Use our graph to track the performance of IMGN stocks over time.ImmunoGen shares at a glance
Latest market close | $3.93 |
---|---|
52-week range | $3.10 - $6.63 |
50-day moving average | $4.35 |
200-day moving average | $4.93 |
Wall St. target price | $12.33 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.86 |
Buy ImmunoGen stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy ImmunoGen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ImmunoGen price performance over time
Historical closes compared with the close of $3.93 from 2023-03-20
1 week (2023-03-15) | -4.15% |
---|---|
1 month (2023-02-22) | -0.51% |
3 months (2022-12-22) | -16.03% |
6 months (2022-09-22) | -16.38% |
1 year (2022-03-21) | -8.60% |
---|---|
2 years (2021-03-22) | -54.72% |
3 years (2020-03-20) | 61.07% |
5 years (2018-03-21) | 12.5 |
ImmunoGen financials
Revenue TTM | $108.8 million |
---|---|
Gross profit TTM | $-104,764,000 |
Return on assets TTM | -31.57% |
Return on equity TTM | -92.61% |
Profit margin | -204.93% |
Book value | $0.69 |
Market capitalisation | $922.3 million |
TTM: trailing 12 months
ImmunoGen share dividends
We're not expecting ImmunoGen to pay a dividend over the next 12 months.
ImmunoGen share price volatility
Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.1 up to $6.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 0.9442. This would suggest that ImmunoGen's shares are less volatile than average (for this exchange).
ImmunoGen overview
ImmunoGen, Inc. , a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc. ; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc. ; CytomX Therapeutics, Inc.
ImmunoGen in the news
ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call Transcript

Q4 2022 ImmunoGen Inc Earnings Call
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Frequently asked questions
What percentage of ImmunoGen is owned by insiders or institutions?Currently 0.403% of ImmunoGen shares are held by insiders and 93.104% by institutions. How many people work for ImmunoGen?
Latest data suggests 277 work at ImmunoGen. When does the fiscal year end for ImmunoGen?
ImmunoGen's fiscal year ends in December. Where is ImmunoGen based?
ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451-1477 What is ImmunoGen's ISIN number?
ImmunoGen's international securities identification number is: US45253H1014 What is ImmunoGen's CUSIP number?
ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101
More guides on Finder
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Ask an Expert